WJ35435 is a dual-targeted anticancer hybrid that induces anti- HDAC (in particular HDAC1 and HDAC6 ) and anti- topoisomerase I activities that causes DNA damage associated with a low DNA repair capability and induces cell cycle arrest at G1- and G2-phase to apoptosis. WJ35435 induces histone H3 acetylation and phosphorylation, α-tubulin acetylation and γ-H2AX formation to achieve anti- HDAC effect. WJ35435 is promising for research of cancer.